Login to Your Account



Financings Roundup

Jounce Gets $47M Series A, Seeks to Jolt Cancer Therapy

By Marie Powers
Staff Writer

Wednesday, February 13, 2013
financings_resized.jpg

Third Rock Ventures LLC plumbed its considerable network and assembled a team of prestigious cancer biologists and immunotherapy experts to form Jounce Therapeutics Inc., which launched Thursday with a $47 million Series A financing.

Based in Cambridge, Mass., the company will seek to discover and develop first-in-class cancer immunotherapies in a space that has drawn enormous interest since the FDA approvals of immune-stimulating targeted therapeutics Provenge (sipuleucel-T, Dendreon Inc.) and Yervoy (ipilimumab, Bristol-Myers Squibb Co.).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription